Inclusion in AD treatment trials however requires more exacting patient screening to assure the correct pathologic diagnosis for study entry, with accumulated Hp tau and amyloid β-protein oligomers (Aβ) confirmed by testing [5,6,7,8]. Here, MAPT is linked to Alzheimer disease.